New equity awards for SOPHiA GENETICS (SOPH) Chief Medical Officer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported new equity awards. He received a grant of 164,671 share options with an exercise price of $5.04 per share, and a separate grant of 112,936 ordinary shares in the form of restricted stock units.
The RSUs were granted under the company’s 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. The options vest as to 25% of the underlying ordinary shares on April 2, 2027, then in equal monthly installments through April 2, 2030, and expire on April 2, 2036. After these awards, Menu directly holds 112,936 ordinary shares and 164,671 share options from this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Menu Philippe
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 164,671 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 112,936 | $0.00 | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 164,671 shares (Direct);
Ordinary Shares — 112,936 shares (Direct)
Footnotes (1)
- Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Share options granted: 164,671 options
Option exercise price: $5.04 per share
RSUs granted: 112,936 RSUs
+5 more
8 metrics
Share options granted
164,671 options
Grant on April 2, 2026 to Chief Medical Officer
Option exercise price
$5.04 per share
Exercise price for 164,671 share options
RSUs granted
112,936 RSUs
Restricted stock unit grant on April 2, 2026
RSU vesting start
25% on April 2, 2027
Initial vesting tranche for RSU award
RSU final vesting date
April 2, 2030
Quarterly vesting of remaining 75% through this date
Option vesting schedule
25% on April 2, 2027; monthly to April 2, 2030
Vesting terms for share option grant
Option expiration
April 2, 2036
Expiration date of 164,671 share options
Shares held following grant
112,936 ordinary shares
Total non-derivative holdings after RSU award
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, contingent right to receive one ordinary share, vest, +2 more
6 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right"
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did SOPHiA GENETICS (SOPH) Chief Medical Officer report on this Form 4?
The Form 4 reports equity compensation awards to Chief Medical Officer Philippe Menu. He received 164,671 share options at a $5.04 exercise price and 112,936 restricted stock units, all granted on April 2, 2026, subject to multi‑year vesting schedules tied to continued service.
How many restricted stock units did SOPHiA GENETICS (SOPH) grant and how do they vest?
SOPHiA GENETICS granted 112,936 restricted stock units to Philippe Menu. Each RSU equals one ordinary share. Twenty‑five percent vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, contingent on his continued service with the company.
Under which plan were the SOPHiA GENETICS (SOPH) RSUs granted to the CMO?
The RSUs granted to Chief Medical Officer Philippe Menu were issued under SOPHiA GENETICS’ 2021 Equity Incentive Plan. This plan provides equity‑based awards such as restricted stock units to key personnel, tying part of their compensation to the company’s share performance and long‑term service.